Document is current
Any future updates will be listed below
-
Authors
Tang, Stephen https://orcid.org/0000-0001-5492-9796
Žedaveinytė, Rimantė https://orcid.org/0000-0002-0738-6976
Burman, Nathaniel https://orcid.org/0000-0002-3732-3159
Pandey, Shishir https://orcid.org/0000-0002-7531-1538
Ramirez, Josephine L.
Kulber, Louie M. https://orcid.org/0000-0001-5625-7372
Wiegand, Tanner https://orcid.org/0000-0002-0528-268X
Wilkinson, Royce A. https://orcid.org/0000-0001-8831-2081
Ma, Yanzhe
Zhang, Dennis J. https://orcid.org/0000-0002-6871-9842
Lampe, George D. https://orcid.org/0000-0002-2873-2372
Berisa, Mirela https://orcid.org/0000-0001-7347-9823
Jovanovic, Marko
Wiedenheft, Blake https://orcid.org/0000-0001-9297-5304
Sternberg, Samuel H. https://orcid.org/0000-0001-8240-9114
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 20 May 2025
First Online: 28 May 2025
Competing interests
: S.H.S. is a co-founder and scientific advisor to Dahlia Biosciences, a scientific advisor to CrisprBits and Prime Medicine, and an equity holder in Dahlia Biosciences and CrisprBits. B.W. is the founder of SurGene and is listed as an inventor on patent applications related to CRISPR–Cas systems and applications thereof. The other authors declare no competing interests.
